Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 196

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron

Open access
Aapro, M., Österborg, A., Gascón, P., Ludwig, H., Beguin, Y.·2012·Annals of Oncology

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mds112

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 69

  1. Ludwig, 2004, The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients, Eur J Cancer, 40, 2293, 10.1016/j.ejca.2004.06.019 · DOI · Paper page
  2. Beale, 2005, The prevalence of iron deficiency among patients presenting with colorectal cancer, Colorectal Dis, 7, 398, 10.1111/j.1463-1318.2005.00789.x · doi:10.1111/j.1463-1318.2005.00789.x
  3. Kuvibidila, 2004, Serum ferritin levels and transferrin saturation in men with prostate cancer, J Natl Med Assoc, 96, 641
  4. Krayenbuehl, 2011, Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration, Blood, 118, 3222, 10.1182/blood-2011-04-346304 · DOI · Paper page
  5. Aapro, 2008, September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents, Oncologist, 13, 33, 10.1634/theoncologist.13-S3-33 · DOI · Paper page
  6. Bokemeyer, 2007, EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update, Eur J Cancer, 43, 258, 10.1016/j.ejca.2006.10.014 · DOI · Paper page
  7. National Comprehensive Cancer Network Inc, 2012, NCCN Practice Guidelines in Oncology; Cancer and Chemotherapy-Induced Anemia—v.2
  8. Rizzo, 2010, American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer, Blood, 116, 4045, 10.1182/blood-2010-08-300541 · DOI · Paper page
  9. Auerbach, 2004, Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial, J Clin Oncol, 22, 1301, 10.1200/JCO.2004.08.119 · DOI · Paper page
  10. Auerbach, 2010, Darbepoetin alfa 300 or 500 ug once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia, Am J Hematol, 85, 655, 10.1002/ajh.21779 · DOI
  11. Bastit, 2008, Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia, J Clin Oncol, 26, 1611, 10.1200/JCO.2006.10.4620 · DOI · Paper page
  12. Hedenus, 2007, Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study, Leukemia, 21, 627, 10.1038/sj.leu.2404562 · DOI · Paper page
  13. Henry, 2007, Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy, Oncologist, 12, 231, 10.1634/theoncologist.12-2-231 · DOI · Paper page
  14. Pedrazzoli, 2008, Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha, J Clin Oncol, 26, 1619, 10.1200/JCO.2007.12.2051 · DOI · Paper page
  15. Dangsuwan, 2010, Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy, Gynecol Oncol, 116, 522, 10.1016/j.ygyno.2009.12.004 · DOI
  16. Kim, 2007, Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy, Gynecol Oncol, 105, 199, 10.1016/j.ygyno.2006.11.014 · DOI
  17. Steinmetz, 2010, A new concept for the differential diagnosis and therapy of anaemia in cancer patients, Support Care Cancer, 19, 261, 10.1007/s00520-010-0812-2 · DOI
  18. Beguin, 2009, A prospective observational study exploring the impact of iron status on response to darbepoetin alfa in patients with chemotherapy induced anemia, Blood, 114, 10.1182/blood.V114.22.2007.2007 · doi:10.1182/blood.v114.22.2007.2007
  19. Ludwig, 2011, High prevalence of iron deficiency across different tumors correlates with anemia, increases during cancer treatment and is associated with poor performance status, Haematologica, 96
  20. Caro, 2001, Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review, Cancer, 91, 2214, 10.1002/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P · DOI · Paper page
  21. Nissenson, 2005, Economic burden of anemia in an insured population, J Manag Care Pharm, 11, 565, 10.18553/jmcp.2005.11.7.565 · DOI
  22. Crawford, 2002, Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy, Cancer, 95, 888, 10.1002/cncr.10763 · DOI · Paper page
  23. Grotto, 2008, Anaemia of cancer: an overview of mechanisms involved in its pathogenesis, Med Oncol, 25, 12, 10.1007/s12032-007-9000-8 · DOI
  24. Fillet, 1989, Model of reticuloendothelial iron metabolism in humans: abnormal behavior in idiopathic hemochromatosis and in inflammation, Blood, 74, 844, 10.1182/blood.V74.2.844.844 · DOI
  25. Van Wyck, 2004, Labile iron in parenteral iron formulations: a quantitative and comparative study, Nephrol Dial Transplant, 19, 561, 10.1093/ndt/gfg579 · DOI
  26. Brugnara, 1993, Red blood cell regeneration induced by subcutaneous recombinant erythropoietin: iron-deficient erythropoiesis in iron-replete subjects, Blood, 81, 956, 10.1182/blood.V81.4.956.956 · DOI
  27. Weiss, 2009, Iron metabolism in the anemia of chronic disease, Biochim Biophys Acta, 1790, 682, 10.1016/j.bbagen.2008.08.006 · DOI · Paper page
  28. Groopman, 1999, Chemotherapy-induced anemia in adults: incidence and treatment, J Natl Cancer Inst, 91, 1616, 10.1093/jnci/91.19.1616 · DOI · Paper page
  29. Tas, 2002, Anemia in oncology practice: relation to diseases and their therapies, Am J Clin Oncol, 25, 371, 10.1097/00000421-200208000-00011 · DOI
  30. Untch, 2009, Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer, J Clin Oncol, 27, 2938, 10.1200/JCO.2008.20.3133 · DOI
  31. Wish, 2006, Assessing iron status: beyond serum ferritin and transferrin saturation, Clin J Am Soc Nephrol, 1, S4, 10.2215/CJN.01490506 · DOI · Paper page
  32. Beguin, 2002, Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients, Haematologica, 87, 1209
  33. Thomas, 2006, The diagnostic plot: a concept for identifying different states of iron deficiency and monitoring the response to epoetin therapy, Med Oncol, 23, 23, 10.1385/MO:23:1:23 · DOI
  34. Ludwig, 2010, High prevalence of iron deficiency in patients with various hematological and malignant diseases: a single center study in 1989 sequential patients, Haematologica, 95
  35. Vamvakas, 2009, Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention, Blood, 113, 3406, 10.1182/blood-2008-10-167643 · DOI · Paper page
  36. Marik, 2008, Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature, Crit Care Med, 36, 2667, 10.1097/CCM.0b013e3181844677 · DOI · Paper page
  37. Thomson, 2009, Patient blood management—a new paradigm for transfusion medicine?, ISBT Science Series, 4, 423, 10.1111/j.1751-2824.2009.01251.x · DOI
  38. Rawn, 2008, The silent risks of blood transfusion, Curr Opin Anaesthesiol, 21, 664, 10.1097/ACO.0b013e32830f1fd1 · DOI
  39. Amato, 1998, Effect of perioperative blood transfusions on recurrence of colorectal cancer: meta-analysis stratified on risk factors, Dis Colon Rectum, 41, 570, 10.1007/BF02235262 · DOI
  40. Bohlius, 2009, Erythropoietin or darbepoetin for patients with cancer—meta-analysis based on individual patient data, Cochrane Database Syst Rev, 10.1002/14651858.CD007303.pub2 · DOI
  41. Gabrilove, 2001, Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing, J Clin Oncol, 19, 2875, 10.1200/JCO.2001.19.11.2875 · DOI · Paper page
  42. Littlewood, 2001, Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial, J Clin Oncol, 19, 2865, 10.1200/JCO.2001.19.11.2865 · DOI · Paper page
  43. Ludwig, 2009, Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study, Eur J Cancer, 45, 1603, 10.1016/j.ejca.2009.02.003 · DOI
  44. Macdougall, 1999, Strategies for iron supplementation: oral versus intravenous, Kidney Int Suppl, 69, S61, 10.1046/j.1523-1755.1999.055Suppl.69061.x · DOI · Paper page
  45. Steensma, 2011, Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia, J Clin Oncol, 29, 97, 10.1200/JCO.2010.30.3644 · DOI
  46. Gafter-Gvili, 2010, Intravenous iron supplementation for the treatment of cancer-related anemia—systematic review and meta-analysis, Blood, 116, 10.1182/blood.V116.21.4249.4249 · doi:10.1182/blood.v116.21.4249.4249
  47. Petrelli, 2012, Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials, J Cancer Res Clin Oncol, 138, 179, 10.1007/s00432-011-1072-3 · DOI
  48. Steensma, 2011, Reply to M. Aapro et al, J Clin Oncol, 29, e527, 10.1200/JCO.2011.35.4597 · doi:10.1200/jco.2011.35.4597
  49. Aapro, 2011, Too-low iron doses and too many dropouts in negative iron trial?, J Clin Oncol, 29, e525, 10.1200/JCO.2011.35.3219 · doi:10.1200/jco.2011.35.3219
  50. Steensma, 2011, The relationship between serum hepcidin levels and clinical outcomes in patients with chemotherapy-associated anemia treated in a controlled trial, J Clin Oncol, 29, 10.1200/jco.2011.29.15_suppl.9031 · DOI
  51. Hedenus, 2008, Economic evaluation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy, J Clin Pharm Ther, 33, 365, 10.1111/j.1365-2710.2008.00924.x · DOI
  52. Steinmetz, 2011, Ferric carboxymaltose for the correction of cancer- and chemotherapy-associated anemia in clinical practice, Haematologica, 96
  53. Evstatiev, 2011, FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease, Gastroenterology, 141, 846, 10.1053/j.gastro.2011.06.005 · DOI · Paper page
  54. Kulnigg, 2008, A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial, Am J Gastroenterol, 103, 1182, 10.1111/j.1572-0241.2007.01744.x · DOI · Paper page
  55. Bailie, 2011, Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America, Drug Res, 61, 267
  56. Bailie, 2005, Hypersensitivity reactions and deaths associated with intravenous iron preparations, Nephrol Dial Transplant, 20, 1443, 10.1093/ndt/gfh820 · DOI · Paper page
  57. Chertow, 2006, Update on adverse drug events associated with parenteral iron, Nephrol Dial Transplant, 21, 378, 10.1093/ndt/gfi253 · DOI · Paper page
  58. Rottembourg, 2011, Do two intravenous iron sucrose preparations have the same efficacy?, Nephrol Dial Transplant, 26, 3262, 10.1093/ndt/gfr024 · DOI
  59. Schellekens, 2011, The therapeutic equivalence of complex drugs, Regul Toxicol Pharmacol, 59, 176, 10.1016/j.yrtph.2010.09.021 · DOI
  60. Aronoff, 2004, Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens, Kidney Int, 66, 1193, 10.1111/j.1523-1755.2004.00872.x · DOI
  61. Zhang, 2008, Post-transcriptional modulation of iron homeostasis during p53-dependent growth arrest, J Biol Chem, 283, 33911, 10.1074/jbc.M806432200 · DOI
  62. Baliga, 1998, In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity, Kidney Int, 53, 394, 10.1046/j.1523-1755.1998.00767.x · DOI · Paper page
  63. Minotti, 2004, Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity, Pharmacol Rev, 56, 185, 10.1124/pr.56.2.6 · DOI · Paper page
  64. Hasinoff, 2008, Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib, Mol Pharmacol, 74, 1722, 10.1124/mol.108.050104 · DOI
  65. Kamba, 2007, Mechanisms of adverse effects of anti-VEGF therapy for cancer, Br J Cancer, 96, 1788, 10.1038/sj.bjc.6603813 · DOI · Paper page
  66. Bergeron, 1985, Influence of iron on in vivo proliferation and lethality of L1210 cells, J Nutr, 115, 369, 10.1093/jn/115.3.369 · DOI
  67. Carthew, 1997, Iron promotes DEN initiated GST-P foci in rat liver, Carcinogenesis, 18, 599, 10.1093/carcin/18.3.599 · DOI
  68. Auerbach, 2009, What is the right balance between iron and erythropoiesis stimulating agents in chemotherapy induced anemia?, Eur J Clin Med Oncol, 1, 7
  69. Beguin, 2008, Darbepoetin-alfa and i.v. iron administration after autologous hematopoietic stem cell transplantation: a prospective randomized multicenter trial, Blood, 112, 10.1182/blood.V112.11.54.54 · doi:10.1182/blood.v112.11.54.54

Cited by

See all 196

Metadata

Authors
Aapro, M., Österborg, A., Gascón, P., Ludwig, H., & Beguin, Y.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2012-08
Volume
23
Issue
8
Pages
1954-1962
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2123275842
Cited by
196
References
3
FWCI
10.37
Type
journal article
Language
en
Open access
bronze
Licence
Funders
Vifor Pharma Ltd

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. https://app.cochat.ai/papers/10.1093/annonc/mds112
The paper
Aapro, M., Österborg, A., Gascón, P., Ludwig, H., & Beguin, Y. (2012). Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Annals of Oncology. https://doi.org/10.1093/annonc/mds112

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.